Pasithea Therapeutics Corp.

NasdaqCM KTTA

Pasithea Therapeutics Corp. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024

Pasithea Therapeutics Corp. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Pasithea Therapeutics Corp. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2023 was -734.24%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: KTTA

Pasithea Therapeutics Corp.

CEO	Dr. Tiago Reis Marques M.D., Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	1111 Lincoln Road
Employees	8
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Key trends

Past 5 years